Trial results

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

NCT07046273 on ClinicalTrials.gov · last registry update 2025-07-01

Registered but not yet open, with 496 participants planned. Due to report 1 August 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Change in HbA1c from baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Shandong New Time Pharmaceutical Co., LTD

Sponsor type

Industry

Enrollment

496

Started

2025-08-01

Primary completion

2028-08-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from baseline

Conditions studied

Type 2 Diabetes (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.